Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Tauopathies are a diverse group of neurodegenerative diseases characterized by the presence of Tau inclusions in neurons and glia. Rather than the classic steps in the transformation of Tau into neurofibrillary tangles, as first studied in Alzheimer's disease, studies on tauopathies reveal the presence of diverse Tau aggregates that appear to be disease-specific. Regardless, the phosphorylation and hyperphosphorylation of Tau, involving various kinases and phosphatases, appear to be central to all tauopathies. As in other neurodegenerative diseases, calcium dysregulation is an early event in multiple tauopathies, where it activates calmodulin to effect downstream events. Here, the events of Tau phosphorylation and hyperphosphorylation, which involve several CaM-dependent kinases and a single CaM-regulated phosphatase, are covered. In addition, CaM has been linked to other events, including Tau aggregation. As a central player in tauopathies, CaM offers several alternative therapeutic routes that are worth investigating. For example, evidence is presented here that supports targeting specific binding motifs of key CaM-regulated Tau kinases as a novel therapeutic approach.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12384000PMC
http://dx.doi.org/10.3390/biom15081133DOI Listing

Publication Analysis

Top Keywords

tau
8
neurodegenerative diseases
8
phosphorylation hyperphosphorylation
8
tauopathies
6
tauopathies calmodulin
4
calmodulin regulates
4
regulates tau
4
tau hyperphosphorylation
4
hyperphosphorylation transformation
4
transformation disease-specific
4

Similar Publications

Alzheimer's Disease (AD) is the leading cause of dementia worldwide, with significant cognitive and behavioural impairments that devastate individuals and their families. Cohort-level findings, demonstrate the broader population-level implications of Sleep and Circadian Rhythm Disruption (SCRD) in AD and underscore the need for early interventions, emphasizing the importance of timely action. However, the mechanism remains unclear.

View Article and Find Full Text PDF

Lifetimes of the Metastable 6d ^{2}D_{5/2} and 6d ^{2}D_{3/2} State of Ra^{+}.

Phys Rev Lett

August 2025

the University of Maryland, National Institute of Standards and Technology, University of Delaware, Department of Physics and Astronomy, Newark, Delaware 19716, USA and Joint Quantum Institute, College Park, Maryland 20742, USA.

We report lifetime measurements of the metastable 6d ^{2}D_{5/2} and 6d ^{2}D_{3/2} states of Ra^{+}. The measured lifetimes, τ_{5}=303.8(1.

View Article and Find Full Text PDF

BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder. While AD diagnosis traditionally relies on clinical criteria, recent trends favor a precise biological definition. Existing biomarkers efficiently detect AD pathology but inadequately reflect the extent of cognitive impairment or disease heterogeneity.

View Article and Find Full Text PDF

Background: As a common postoperative neurological complication, postoperative delirium (POD) can lead to poor postoperative recovery in patients, prolonged hospitalization, and even increased mortality. However, POD's mechanism remains undefined and there are no reliable molecular markers of POD to date. The present work examined the associations of cerebrospinal fluid (CSF) sTREM2 with CSF POD biomarkers, and investigated whether the effects of CSF sTREM2 on POD were modulated by the core pathological indexes of POD (Aβ42, tau, and ptau).

View Article and Find Full Text PDF

Objective: The objective of this study was to determine the predictive value of amyloid-positron emission tomography (PET) versus the plasma ratio of phosphorylated tau at threonine 217 (p-tau217) to non-phosphorylated tau217 (%p-tau217) for tau-PET transitions (T- to T+). The added value of combining plasma amyloid-β 42 and amyloid-β 40 (Aβ42/40) and %p-tau217 into an amyloid probability score (APS2) was also assessed.

Methods: Mayo Clinic Study of Aging (MCSA) participants had plasma markers measured at via mass spectrometry (MS), an amyloid-PET scan, and a tau-PET (meta-temporal region of interest [ROI]) negative scan (standardized uptake value ratio [SUVR] <1.

View Article and Find Full Text PDF